Hemophilia Treatment Market accounted for US$ 12.45 billion in 2020 and is estimated to be US$ 22.41 billion by 2030 and is anticipated to register a CAGR of 6.1%. Hemophilia is an inherited genetic disorder which disables the body\'s ability to make blood clots, a very important process needed to stop bleeding. Hence, Hemophilia leads to uncontrolled bleeding after the injury and can event lead to death. The main type of hemophilia are hemophilia A, and hemophilia B, and hemophilia A occurs due to deficiency of clotting factor VIII and hemophilia B, occurs deficiency of clotting factor IX. Hemophilia is generally treated with genetically engineered clotting factor medicines which prevent and treat prolonged bleeding. According to the Centers of Disease Control and Prevention, Hemophilia A affects 1 in 5,000 male births and around 400 babies are born with hemophilia A each year. According to the same source currently, the number of people with hemophilia in the U.S is estimated to be about 20,000.
The report " Global Hemophilia Treatment Market, By Product (Recombinant coagulation factor concentrates, Plasma derived coagulation factor concentrates, Antifibrinolytic agents, and Desmopressin), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C) By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospitals, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030”
Key Highlights:
· In 2020, Novo Nordisk has announced the launch of ESPEROCT, the company’s long-acting recombinant factor VIII product for the prevention and treatment of bleeding in individuals with hemophilia A. The new therapy is specifically indicated for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment, control of bleeding episodes and perioperative management of bleeding.
· In 2020, The U.S. Food and Drug Administration approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies). Sevenfact contains an active ingredient expressed in genetically engineered rabbits.
Analyst View:
Key players in the market are focusing on gaining approval of its novel hemophilia treatment drugs in key regions such as Europe and Asia-Pacific. Approval of such drugs in key regions is expected to fuel market growth over forecast period. For instance, in August 2018, Bayer AG’s hemophilia treatment drug Jivi received approval in Europe and in September 2018, Jivi also received approval in Japan.
Before purchasing this report, request a sample or make an inquiry by clicking the following link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/141
Key Market Insights from the report:
The Global Hemophilia Treatment Market accounted for US$ 12.45 billion in 2020 and is estimated to be US$ 22.41 billion by 2030 and is anticipated to register a CAGR of 6.1%. The global hemophilia treatment market has been segmented on the basis of drug type, disease type, distribution channel and region.
· By Drug Type, the market is segmented into drug type, recombinant coagulation factor concentrates, plasma derived coagulation factor concentrates, antifibrinolytic agents, and desmopressi.
· By Disease Type, the market is segmented into Hemophilia A, Hemophilia B, and Hemophilia C.
· By Distribution Channel, the market is segmented into retail pharmacies, online pharmacies, and hospitals.
· By Region, the Global Diabetic Neuropathy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Competitive Landscape:
Key players operating in the global hemophilia treatment market includes Baxter International, Inc., Hospira, Inc., Baxalta, Novo Nordisk, BiogenInc., Pfizer, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Kedrion, Octapharma AG, Sanofi SA, Shire Plc., and Swedish Orphan Biovitrum AB.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
